November & December
2005
From Janis and Friends:
Nov
11 - 15, 2005 San Francisco, CA
Join our Forum in order to discuss the AASLD
Or
click below and enter as our guest to read the conference news
HIVandHepatitis.com Coverage of Highlights from the
HCV Advocate’s AASLD Conference coverage
October 2005
What's the Hepatitis Virus All About?
Randomized Trial
of Valopicitabine (NM283), Alone or with Peg-Interferon, vs.
Retreatment with Peg-Interferon plus Ribavirin (PegIFN/RBV) in Hepatitis C
Patients with Previous Non-Response to PegIFN/RBV: First Interim Results
Short Course
PegIntron plus Rebetol Approved in Europe for HCV Patients with Genotype 1
and Low HCV Viral Load
New HCV Protease
Inhibitor VX-950
Viral load level at week 8 may be as accurate as
"12-week rule" for predicting failure to achieve SVR in HCV patients
September 2005
Locteron, New
Interferon: Once Every Two weeks
Most chronic hepatitis C sufferers will develop
cirrhosis in later life
A new player in the battle against hepatitis prevents
inflammation and the death of liver cells
Calcineurin Inhibitors and Hepatitis C: Current Views
and Future Perspectives
Low Levels of HCV
Persist Years After Sustained Virologic Response
Coffee Drinking May Keep Liver Cancer at Bay
Can treating HCV
prevent progression to cirrhosis?
August 2005
Roche Launches
New Campaign to Educate Consumers About Hepatitis C
European regulators have recommended the approval of
revised dosing instructions for Schering-Plough Corporation's hepatitis C
combination therapy
Should Liver
Biopsy Be Recommended Only as a Second Line Test in Chronic Hepatitis C
Patients?
Cambridge, Massachusetts-based Idenix Pharmaceuticals
and Swiss drugmaker Novartis AG have revealed that their experimental drug
for hepatitis B has achieved its primary goal in a phase III trial.
July 2005
Individualized
Versus Standard Treatment HCV
July 15 2005
Daily cannabis
smoking as a risk factor for progression of fibrosis in chronic hepatitis C
July 08 2005
Italian Study Links
Tobacco Use and Hepatitis C to Development of Non-Hodgkin’s Lymphoma
July 08 2005
Optimal Dosing
Frequency of Pegylated Interferon Alfa-2b (PegIntron) Monotherapy
12 Weeks of
Peginterferon Alfa-2b (PegIntron) and Ribavirin Combination Therapy Shown as
Effective as 24 Weeks of Treatment in HCV Patients with Genotype 2 or 3
Virus Who Had an Early Virological Response to Therapy
Trial Results of 'PEGASYS' Plus Ribavirin 'COPEGUS', a
Combination Therapy for Hepatitis C, Presented at the 41st Annual Conference
of the Japan Society of Hepatology
June 2005
Novartis in
licensing deal on Hep C drug
June 03 2005
New HCV Drug
Albuferon Starts Study in Genotype 1 Naives
June 04 2005
Combination
Therapy of Low Dose Ribavirin and Pegylated Interferon for Patients with HCV
and End-Stage Renal Disease on Dialysis
Report from DDW
2005 – Part 1
No Benefit from
Prolonging Treatment with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus)
in HIV-HCV Co-Infected Patients without an Early Virological Response
Etanercept
Treatment to Slow Fibrosis Progression Shows No Histological or Biochemical
Improvement in Chronic HCV Genotype 1 Nonresponders to Peginterferon/Ribavirin
May 2005
From Janis and Friends:
May 14 - 19, 2005
Digestive Disease Week 2005 (DDW
2005)
From HIV and Hepatitis :
Update From EASL 2005:
HCV drugs in
clinical development as well as some interesting data on Pegasys and
PegIntron that will be discussed in this article
Enhanced Response
to Peginterferon Alfa-2a (Pegasys)-based Triple Therapy in Previously
Non-responsive HCV Patients: Final Results of the PRETTY Study
Sexual Transmission
New HCV Therapies
Show Promise: Etanercept and Lambda Interferon
Diabetes & Lipids
Associated with Liver Disease
April 2005
From Janis and Friends:
April 13-17 2005
(40th EASL)
From HIV and Hepatitis Site:
Highlights from the
40th
Annual meeting of the European Association for the Study of the Liver (40th
EASL)
April 13 - 17, 2005, Paris, France
Peginterferon
alfa-2a and alfa-2b equally effective for chronic hepatitis C in small,
retrospective study
Testing at 24 weeks
Research offers hope of new treatments for liver
damage
Impact of
hepatitis C on health related quality of life: A systematic review and
quantitative assessment
Combating HCV Fatigue
Hepatitis C
Antibodies May Be Slow to Appear
Hepatitis C: The silent epidemic
March 2005
Interferon Beta
Is Effective for Early Retreatment of Relapsers with Genotype 1b and Low HCV
Viral Load
Mar 23 2005
Interferon's
Benefits for Fibrosis Studied
Mar 16 2005
When Does
Mother-to-Child Transmission of Hepatitis C Virus Occur?
Swedish study links HCV infection with hematologic
malignancies
Why is HCV So Resilient?
Mar 02 2005
FDA Approvals: Atacand, Pegasys Plus Copegus, Triage
APAP TOX Screen
Texas scientists discover how hepatitis C
short-circuits the immune system
Ribavirin Plays
Critical Role in the Response to Peginterferon-based Anti-HCV Therapy
February 2005
Effects
of Peginterferon Alfa-2b (Peg-Intron) and Ribavirin on Early Hepatitis C
Virus Dynamics and on Prediction of Sustained Viral Response
Feb 16 2005
HCV Patients
Whose ALT Levels Are Less Than Twice the Upper Limit of Normal After
Interferon Therapy Have Decreased Risk of Liver Cancer
Feb 16 2005
Peginterferon
Alfa-2a (Pegasys) for Hepatitis C Recurrence After Liver Transplantation
Feb 14 2005
A 65% SVR Rate
Reported in Liver Transplant Patients Treated with Standard Interferon
Alfa-2b or Peginterferon Alfa-2b (Peg-Intron) in Combination with Ribavirin
Feb 14 2004
Nine of 10
Chronic Hepatitis C Patients Achieve a Cure 24 Weeks Post-treatment with
High Dose Ribavirin Plus Standard Dose Peginterferon Alfa-2a (Pegasys)
Feb 11 2005
January 2005
Researcher Cites “Potential Bias" Toward Peg Intron in New Trial
Jan 12 2005
|